DCR

mEC - (neo)adjuvant (NA) metastatic/advanced - esophageal cancer (mEC) mEC - (neo)adjuvant (NA)

versus placebo
nivolumab alone vs. placebo 1 -

mEC - 1st line (L1) metastatic/advanced - esophageal cancer (mEC) mEC - 1st line (L1)

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 -

mEC - 2nd line (L2) metastatic/advanced - esophageal cancer (mEC) mEC - 2nd line (L2)

versus Standard of Care (SoC)
camrelizumab alone vs. Standard of Care (SoC) 1 -
nivolumab alone vs. Standard of Care (SoC) 1 certainty unassessable-59%
pembrolizumab alone vs. Standard of Care (SoC) 1 -